IFM Investors Pty Ltd raised its position in shares of The Clorox Company (NYSE:CLX – Get Rating) by 18.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,944 shares of the company’s stock after buying an additional 2,905 shares during the period. IFM Investors Pty Ltd’s holdings in Clorox were worth $2,634,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp increased its holdings in shares of Clorox by 4.1% in the fourth quarter. State Street Corp now owns 8,223,034 shares of the company’s stock valued at $1,433,768,000 after purchasing an additional 327,488 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Clorox in the fourth quarter valued at approximately $48,724,000. Candlestick Capital Management LP acquired a new stake in shares of Clorox in the fourth quarter valued at approximately $44,971,000. Nuance Investments LLC increased its holdings in shares of Clorox by 250.8% in the fourth quarter. Nuance Investments LLC now owns 351,858 shares of the company’s stock valued at $61,350,000 after purchasing an additional 251,543 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in shares of Clorox by 18.6% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,281,902 shares of the company’s stock valued at $223,512,000 after purchasing an additional 201,306 shares in the last quarter. 77.28% of the stock is owned by institutional investors.
Shares of NYSE CLX opened at $140.98 on Friday. The company’s fifty day moving average is $141.85 and its 200-day moving average is $150.47. The stock has a market cap of $17.35 billion, a price-to-earnings ratio of 38.21, a P/E/G ratio of 4.83 and a beta of 0.18. The Clorox Company has a twelve month low of $120.50 and a twelve month high of $191.75. The company has a quick ratio of 0.40, a current ratio of 0.71 and a debt-to-equity ratio of 3.28.
Clorox (NYSE:CLX – Get Rating) last posted its quarterly earnings data on Monday, May 2nd. The company reported $1.31 EPS for the quarter, beating the consensus estimate of $0.97 by $0.34. The business had revenue of $1.81 billion for the quarter, compared to analysts’ expectations of $1.81 billion. Clorox had a net margin of 6.44% and a return on equity of 92.98%. During the same period in the previous year, the firm posted $1.62 EPS. On average, research analysts anticipate that The Clorox Company will post 4.16 EPS for the current fiscal year.
In other Clorox news, COO Eric H. Reynolds sold 585 shares of Clorox stock in a transaction on Monday, May 9th. The shares were sold at an average price of $154.83, for a total value of $90,575.55. Following the sale, the chief operating officer now directly owns 17,289 shares in the company, valued at approximately $2,676,855.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director A D. David Mackay sold 1,000 shares of Clorox stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $140.63, for a total transaction of $140,630.00. Following the completion of the sale, the director now owns 600 shares in the company, valued at $84,378. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.
A number of brokerages recently weighed in on CLX. Barclays lowered their price target on shares of Clorox from $126.00 to $115.00 and set an “underweight” rating for the company in a report on Monday, May 23rd. Wells Fargo & Company lowered their target price on shares of Clorox from $130.00 to $120.00 and set an “underweight” rating for the company in a report on Tuesday, June 21st. JPMorgan Chase & Co. lifted their target price on shares of Clorox from $123.00 to $126.00 in a report on Thursday, April 14th. StockNews.com initiated coverage on shares of Clorox in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, The Goldman Sachs Group lowered their target price on shares of Clorox from $145.00 to $127.00 in a report on Tuesday, March 29th. Nine equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $140.69.
Clorox Company Profile (Get Rating)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.
Want More Great Investing Ideas?
Receive News & Ratings for Clorox Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clorox and related companies with MarketBeat.com’s FREE daily email newsletter.